Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
The trial will be performed to evaluate if BIBF 1120 in combination with standard pemetrexed therapy is more effective than placebo (inactive capsule) plus standard pemetrexed therapy in patients with stage IIIB, IV or recurrent NSCLC. Safety information about BIBF1120/pemetrexed will be obtained.
Inclusion criteria:
Exclusion criteria:
Downy, California, United States
Witchita, Kansas, United States
Bs. As. Codigo Buenos Aires, Argentina
Quilmes Buenos Aires, Argentina
Rosario, Santa Fe, Argentina
Belo Horizonte,Minas Gerais, Brazil
Cachoeira Do Itapemirim-ES, Brazil
Campinas SP, Brazil
Goiania Goias, Brazil
Jau/SP, Brazil
Londrina, Parana, Brazil
Pelotas Rio Grande Do Sul, Brazil
Salvador Bahia, Brazil
Sao Paulo - SP, Brazil
Sorocaba Sao Paulo, Brazil
Monteria, Cordoba, Colombia
Carrasquilla Panama, Panama
Cercado Arequipa, Peru
Daejoen, South Korea
Jeonbuk, South Korea
Balcali-Adana, Turkey (Türkiye)
Dnipropetrovks, Ukraine